Skip to main content

Advertisement

SpringerLink
Log in

Pathogenesis of spondyloarthritis: Insights from synovial membrane studies

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Here, we review histopathologic studies of the cellular and molecular pathways of spondyloarthritis (SpA) synovial inflammation. In contrast with lymphocytes, specific macrophage subsets and polymorphonuclear cells selectively increase in SpA synovitis, correlate with global disease activity, decrease rapidly upon effective treatment with tumor necrosis factor (TNF)-α blockers, and serve as valuable biomarkers for treatment response in SpA. Functionally, increased Toll-like receptor triggering may be responsible for the proinflammatory response of these cells. Therefore, we propose that an exaggerated response of the innate immune system in genetically susceptible patients rather than a classic, lymphocyte-mediated autoimmune process is involved in the pathogenesis of SpA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hammer RE, Maika SD, Richardson JA, et al.: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLAB27-associated human disorders. Cell 1990, 63:1099–1112.

    Article  PubMed  CAS  Google Scholar 

  2. Taurog JD, Richardson JA, Croft JT, et al.: The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994, 180:2359–2364.

    Article  PubMed  CAS  Google Scholar 

  3. Hermann E, Yu DT, Meyer zum Buschenfelde KH, et al.:HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993, 342:646–650.

    Article  PubMed  CAS  Google Scholar 

  4. Dulphy N, Peyrat MA, Tieng V, et al.: Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27. J Immunol 1999, 162:3830–3839.

    PubMed  CAS  Google Scholar 

  5. Popov I, Dela Cruz CS, Barber BH, et al.: The effect of an anti-HLA-B27 immune response on CTL recognition of Chlamydia. J Immunol 2001, 167:3375–3382.

    PubMed  CAS  Google Scholar 

  6. Ugrinovic S, Mertz A, Wu P, et al.: A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. J Immunol 1997, 159:5715–5723.

    PubMed  CAS  Google Scholar 

  7. Kuon W, Kuhne M, Busch DH, et al.: Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy. J Immunol 2004, 173:4859–4866.

    PubMed  CAS  Google Scholar 

  8. Atagunduz P, Appel H, Kuon W, et al.: HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum 2005, 52:892–901.

    Article  PubMed  CAS  Google Scholar 

  9. Zou J, Appel H, Rudwaleit M, et al.: Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis 2005, 64:722–729.

    Article  PubMed  CAS  Google Scholar 

  10. May E, Dorris ML, Satumtira N, et al.: CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J Immunol 2003, 170:1099–1105. This study demonstrates that CD8+ T cells, which have been thought to play a HLA-B27 restricted role in the pathogenesis of spondylarthritis, are not crucial for the pathology in HLA-B27 transgenic animals.

    PubMed  CAS  Google Scholar 

  11. Mear JP, Schreiber KL, Munz C, et al.: Misfolding of HLAB27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999, 163:6665–6670.

    PubMed  CAS  Google Scholar 

  12. Allen RL, O’Callaghan CA, McMichael AJ, Bowness P:Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999, 162:5045–5048.

    PubMed  CAS  Google Scholar 

  13. Kollnberger S, Bird L, Sun MY, et al.: Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 2002, 46:2972–2982.

    Article  PubMed  CAS  Google Scholar 

  14. Chan AT, Kollnberger SD, Wedderburn LR, Bowness P:Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 2005, 52:3586–3595.

    Article  PubMed  CAS  Google Scholar 

  15. Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994, 12:141–179.

    PubMed  CAS  Google Scholar 

  16. Tran TM, Satumtira N, Dorris ML, et al.: HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP. J Immunol 2004, 172:5110–5119.

    PubMed  CAS  Google Scholar 

  17. Ikawa T, Ikeda M, Yamaguchi A, et al.: Expression of arthritis-causing HLA-B27 on Hela cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium. J Clin Invest 1998, 101:263–272.

    Article  PubMed  CAS  Google Scholar 

  18. Penttinen MA, Holmberg CI, Sistonen L, Granfors K: HLAB27 modulates nuclear factor kappaB activation in human monocytic cells exposed to lipopolysaccharide. Arthritis Rheum 2002, 46:2172–2180.

    Article  PubMed  CAS  Google Scholar 

  19. Smeets TJ, Dolhain RJ, Breedveld FC, Tak PP: Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J Pathol 1998, 186:75–81.

    Article  PubMed  CAS  Google Scholar 

  20. Baeten D, Demetter P, Cuvelier C, et al.: Comparative study of synovial histology in rheumatoid arthritis, spondyloarthropathy and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000, 59:945–953.

    Article  PubMed  CAS  Google Scholar 

  21. Baeten D, Kruithof E, De Rycke L, et al.: Diagnostic classi fication of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum 2004, 50:2931–2941.

    Article  PubMed  Google Scholar 

  22. Baeten D, Møller HJ, Delanghe J, et al.: Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004, 50:1611–1623.

    Article  PubMed  Google Scholar 

  23. Canete JD, Martinez SE, Farres J, et al.: Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000, 59:263–268.

    Article  PubMed  CAS  Google Scholar 

  24. Rudwaleit M, Siegert S, Yin Z, et al.: Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001, 60:36–42.

    Article  PubMed  CAS  Google Scholar 

  25. Baeten D, Van Damme N, Van den Bosch F, et al.: Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001, 60:750–755.

    Article  PubMed  CAS  Google Scholar 

  26. Baeten D, Vandooren B, De Rycke L, et al.: Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al. Arthritis Rheum 2004, 50:1015–1016.

    Article  PubMed  Google Scholar 

  27. Sieper J: Mechanisms of action of biologicals in AS. Ann Rheum Dis 2005, 64:S111.

    Article  Google Scholar 

  28. Zou J, Rudwaleit M, Brandt J, et al.: Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003, 62:561–564.

    Article  PubMed  CAS  Google Scholar 

  29. Kraan MC, van Kuijk AW, Dinant HJ, et al.: Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776–2784.

    Article  PubMed  CAS  Google Scholar 

  30. Baeten D, Kruithof E, Van den Bosch F, et al.: Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001, 44:186–195.

    Article  PubMed  CAS  Google Scholar 

  31. Kruithof E, Baeten D, Van den Bosch F, et al.: Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005, 64:529–536.

    Article  PubMed  CAS  Google Scholar 

  32. Kruithof E, De Rycke L, Roth J, et al.: Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005, 52:3898–3909.

    Article  PubMed  CAS  Google Scholar 

  33. De Rycke L, Baeten D, Kruithof E, et al.: Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005, 52:2192–2201.

    Article  CAS  Google Scholar 

  34. Shi S, Ciurli C, Cartman A, et al.: Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum 2003, 48:2903–2915. Here, Shi et al. introduce a new animal model for spondylarthritis in which humoral immunity appears to play an important role.

    Article  PubMed  CAS  Google Scholar 

  35. Baeten D, Demetter P, Cuvelier CA, et al.: Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002, 196:343–350. This article first describes the selective increase of a specific macrophage subset characterized by the expression of the scavenger receptor CD163 in spondylarthritis.

    Article  PubMed  CAS  Google Scholar 

  36. Kruithof E, Baeten D, De Rycke L, et al.: Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7:R569-R580.

    Article  PubMed  CAS  Google Scholar 

  37. Demetter P, De Vos M, Van Huysse JA, et al.: Colon mucosa of patients both with spondylarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2005, 64:321–324.

    Article  PubMed  CAS  Google Scholar 

  38. De Rycke L, Baeten D, Foell D, et al.: Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 2005, 206:17–27.

    Article  CAS  Google Scholar 

  39. Sack U, Stiehl P, Geiler G: Distribution of macrophages in rheumatoid synovial membrane and its association with basic activity. Rheumatol Int 1994, 13:181–186.

    Article  PubMed  CAS  Google Scholar 

  40. Tak PP, Smeets TJ, Daha MR, et al.: Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997, 40:217–225.

    Article  PubMed  CAS  Google Scholar 

  41. Kraan MC, Versendaal H, Jonker M, et al.: Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998, 41:1481–1488.

    Article  PubMed  CAS  Google Scholar 

  42. Smeets TJ, Barg EC, Kraan MC, et al.: Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003, 62:635–638.

    Article  PubMed  CAS  Google Scholar 

  43. Gerlag DM, Haringman JJ, Smeets TJ, et al.: Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004, 50:3783–3791. This work demonstrates that synovial sublining macrophages are good biomarkers of response to treatment in rheumatoid arthritis.

    Article  PubMed  CAS  Google Scholar 

  44. Haringman JJ, Gerlag DM, Zwinderman AH, et al.:Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:834–838.

    Article  PubMed  CAS  Google Scholar 

  45. Baeten D, Kruithof E, De Rycke L, et al.: Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005, 7:R359-R369. This paper indicates that specific synovial features, such as CD163+ macrophages and polymorphonuclear cells, correlate directly with global disease activity and inflammation in spondylarthritis.

    Article  PubMed  Google Scholar 

  46. Paleolog E: The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin Investig Drugs 2003, 12:1087–1095.

    Article  PubMed  CAS  Google Scholar 

  47. Smeets TJ, Kraan MC, van Loon ME, Tak PP: Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155–2162.

    Article  PubMed  CAS  Google Scholar 

  48. Goedkoop AY, Kraan MC, Teunissen MB, et al.: Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004, 63:769–773.

    Article  PubMed  CAS  Google Scholar 

  49. Kane D, Gogarty M, O’leary J, et al.: Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004, 50:3286–3295.

    Article  PubMed  CAS  Google Scholar 

  50. Kruithof E, De Rycke L, Vandooren B, et al.: Identification of synovial biomarkers of response to experimental treatment in early phase clinical trials in spondylarthropathy. Arthritis Rheum 2006, In press.

  51. Hogger P, Dreier J, Droste A, et al.: Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol 1998, 161:1883–1890.

    PubMed  CAS  Google Scholar 

  52. Mantovani A, Sica A, Sozzani S, et al.: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677–686. Article clearly and comprehensively reviews different macrophage subsets.

    Article  PubMed  CAS  Google Scholar 

  53. Kristiansen M, Graversen JH, Jacobsen C, et al.: Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198–201.

    Article  PubMed  CAS  Google Scholar 

  54. Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996, 42:1589–1600.

    PubMed  CAS  Google Scholar 

  55. Droste A, Sorg C, Hogger P: Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun 1999, 256:110–113.

    Article  PubMed  CAS  Google Scholar 

  56. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK:Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002, 99:378–380.

    Article  PubMed  CAS  Google Scholar 

  57. Schebesch C, Kodelja V, Muller C, et al.: Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. Immunology 1997, 92:478–486.

    Article  PubMed  CAS  Google Scholar 

  58. Hogger P, Sorg C: Soluble CD163 inhibits phorbol esterinduced lymphocyte proliferation. Biochem Biophys Res Commun 2001, 288:841–843.

    Article  PubMed  CAS  Google Scholar 

  59. Van den Heuvel MM, Tensen CP, van As JH, et al.: Regulation of CD 163 on human macrophages: cross-linking of CD163 induces signaling and activation. J Leukoc Biol 1999, 66:858–866.

    PubMed  Google Scholar 

  60. Moestrup SK, Moller HJ: CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004, 36:347–354.

    Article  PubMed  CAS  Google Scholar 

  61. Seibl R, Birchler T, Loeliger S, et al.: Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003, 162:1221–1227.

    PubMed  CAS  Google Scholar 

  62. Iwahashi M, Yamamura M, Aita T, et al.: Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004, 50:1457–1467.

    Article  PubMed  CAS  Google Scholar 

  63. Radstake TR, Roelofs MF, Jenniskens YM, et al.: Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004, 50:3856–3865.

    Article  PubMed  CAS  Google Scholar 

  64. Choe JY, Crain B, Wu SR, Corr M: Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J Exp Med 2003, 197:537–542.

    Article  PubMed  CAS  Google Scholar 

  65. Joosten LA, Koenders MI, Smeets RL, et al.: Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003, 171:6145–6153.

    PubMed  CAS  Google Scholar 

  66. De Rycke L, Vandooren B, Kruithof E, et al.: Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005, 52:2146–2158. This study demonstrates the higher expression of TLR2 and TLR4 in spondylarthritis synovitis compared with rheumatoid arthritis and indicates that the expression and function of TLR is modulated by TNF-α blockade in vivo. This is the first study to identify TLR as central players in spondylarthritis.

    Article  CAS  Google Scholar 

  67. Termeer C, Benedix F, Sleeman J, et al.: Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002, 195:99–111.

    Article  PubMed  CAS  Google Scholar 

  68. Johnson GB, Brunn GJ, Kodaira Y, Platt JL: Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002, 168:5233–5239.

    PubMed  CAS  Google Scholar 

  69. Baeten D, Kruithof E, Van den Bosch F, et al.: Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003, 62:829–834.

    Article  PubMed  CAS  Google Scholar 

  70. Netea MG, Radstake T, Joosten LA, et al.: Salmonella septicemia in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003, 48:1853–1857.

    Article  PubMed  CAS  Google Scholar 

  71. Vandooren B, Kruithof E, Yu DT, et al.: Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004, 50:2942–2953.

    Article  PubMed  CAS  Google Scholar 

  72. Ritchlin CT, Haas-Smith SA, Li P, et al.: Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821–831.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Rheumatology, F4-148, Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands

    Dominique Baeten MD, PhD

Authors
  1. Leen De Rycke MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elli Kruithof MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernard Vandooren MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul P. Tak MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dominique Baeten MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominique Baeten MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Rycke, L., Kruithof, E., Vandooren, B. et al. Pathogenesis of spondyloarthritis: Insights from synovial membrane studies. Curr Rheumatol Rep 8, 275–282 (2006). https://doi.org/10.1007/s11926-006-0008-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-006-0008-4

Keywords

Search

Navigation